- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | 291 | GlobeNewswire (Europe) | ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is the next evolution... ► Artikel lesen | |
| 13.05. | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 31.03. | ZyVersa Therapeutics GAAP EPS of -$4.18 | 1 | Seeking Alpha | ||
| 31.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.11.25 | ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results | 207 | GlobeNewswire (Europe) | ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies - Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases... ► Artikel lesen | |
| 03.09.25 | ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression | 282 | GlobeNewswire (Europe) | ZyVersa is developing Cholesterol Efflux Mediator VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys' filtration system. VAR 200 directly removes lipids from... ► Artikel lesen | |
| 13.08.25 | ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones | 541 | GlobeNewswire (Europe) | KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AMYLYX PHARMACEUTICALS | 22,820 | 0,00 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 | ||
| DISC MEDICINE | 77,44 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 43,490 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,79 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Generated second quarter 2026 XDEMVY- net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 53,14 | 0,00 % | Citizens lowers Structure Therapeutics stock price target on GLP agonist | ||
| VERA THERAPEUTICS | 32,850 | -0,12 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen ZYVERSA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.